A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Eculizumab

Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.

Trial Locations (35)

8950

Research Site, Esplugues de Llobregat

10016

Research Site, New York

16132

Research Site, Genova

19019

Clinical Trial Site, Philadelphia

20001

Clinical Trial Site, Washington D.C.

20847

Clinical Trial Site, Rockville

21013

Research Site, Gallarate

21287

Research Site, Baltimore

27514

Clinical Trial Site, Chapel Hill

30301

Clinical Trial Site, Atlanta

33101

Clinical Trial Site, Miami

45711

Research Site, Datteln

48149

Research Site, Münster

63130

Research Site, St Louis

75390

Research Site, Dallas

94016

Clinical Trial Site, San Francisco

95123

Research Site, Catania

02101

Clinical Trial Site, Boston

02115

Research Site, Boston

07601

Research Site, Hackensack

08901

Research Site, New Brunswick

T3B 6A8

Research Site, Calgary

Unknown

Clinical Trial Site, Edmonton

Clinical Trial Site, Toronto

Clinical Trial Site, Regensburger Straße

Clinical Trial Site, Genoa

Clinical Trial Site, Rome

Clinical Trial Site, Yokohama

Clinical Trial Site, Seoul

Clinical Trial Site, Barcelona

Clinical Trial Site, Seville

M5G 1X8

Research Site, Toronto

H3T1C5

Research Site, Montreal

00178

Research Site, Rome

232-0024

Research Site, Yokohama

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY